KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Gross Margin (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Gross Margin for 13 consecutive years, with 89.13% as the latest value for Q4 2025.

  • On a quarterly basis, Gross Margin rose 411.0% to 89.13% in Q4 2025 year-over-year; TTM through Dec 2025 was 89.63%, a 140.0% increase, with the full-year FY2025 number at 89.63%, up 140.0% from a year prior.
  • Gross Margin was 89.13% for Q4 2025 at Supernus Pharmaceuticals, down from 90.13% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 90.13% in Q3 2025 to a low of 82.29% in Q2 2021.
  • A 5-year average of 87.6% and a median of 88.15% in 2023 define the central range for Gross Margin.
  • Peak YoY movement for Gross Margin: plummeted -1109bps in 2021, then surged 568bps in 2022.
  • Supernus Pharmaceuticals' Gross Margin stood at 89.32% in 2021, then dropped by -3bps to 86.28% in 2022, then grew by 2bps to 88.06% in 2023, then decreased by -3bps to 85.01% in 2024, then increased by 5bps to 89.13% in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Gross Margin are 89.13% (Q4 2025), 90.13% (Q3 2025), and 89.83% (Q2 2025).